Symbiotix Biotherapies, Inc. (“Symbiotix”), a pioneering venture-backed microbiome company developing novel molecular therapeutics based on the human microbiome, today announced that it has entered into a license agreement with Harvard University. Under the agreement, Symbiotix […]
Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a clinical programs update and reported financial results for […]
Metagenics, Inc., a health sciences company, has joined the UC San Diego Center for Microbiome Innovation (CMI) as an industry sponsor. CMI encompasses a large range of expertise from microbiome sampling, a broad range of […]
NESS ZIONA, Israel, Jan. 30, 2018 /PRNewswire/ — BiomX Ltd., a microbiome company developing customized phage therapies, today announced that it has exclusively sub-licensed from JSR Corporation a set of bacterial targets for the development and […]
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), is pleased to announce a new global in-licensing agreement with Ab E Discovery to further develop and bring to market an egg antibody […]